TCTC Holdings LLC Lowers Position in Abbott Laboratories $ABT

TCTC Holdings LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 6.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 92,595 shares of the healthcare product maker’s stock after selling 6,222 shares during the period. TCTC Holdings LLC’s holdings in Abbott Laboratories were worth $12,402,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. IMG Wealth Management Inc. increased its holdings in Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares during the period. Cloud Capital Management LLC purchased a new position in shares of Abbott Laboratories in the 3rd quarter valued at $29,000. Guerra Advisors Inc bought a new position in shares of Abbott Laboratories in the 3rd quarter worth $31,000. Anfield Capital Management LLC lifted its stake in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC bought a new stake in Abbott Laboratories during the second quarter valued at about $32,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of recent research reports. Evercore reduced their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Leerink Partners reduced their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Royal Bank Of Canada lowered their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Citigroup reduced their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Finally, Argus lowered their price objective on Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Price Performance

NYSE ABT opened at $112.63 on Friday. The company has a market cap of $195.84 billion, a price-to-earnings ratio of 30.28, a PEG ratio of 1.79 and a beta of 0.75. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The stock’s fifty day moving average price is $119.48 and its 200 day moving average price is $126.40. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, February 13th. Investors of record on Thursday, January 15th were issued a $0.63 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date was Thursday, January 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Insider Buying and Selling

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the purchase, the director directly owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.